Spero therapeutics to present at upcoming investor conference

Cambridge, mass., april 26, 2023 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) (spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that spero's management team will present and be available for one-on-one meetings at the h.c. wainwright bioconnect investor conference at nasdaq in new york city, on may 2, 2023. details are as follows:
SPRO Ratings Summary
SPRO Quant Ranking